BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 3375961)

  • 1. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study.
    McCarthy WH; Shaw HM; Thompson JF; Milton GW
    Surg Gynecol Obstet; 1988 Jun; 166(6):497-502. PubMed ID: 3375961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prognosis after sentinel node biopsy in malignant melanoma].
    Lock-Andersen J; Horn J; Sjøstrand H
    Ugeskr Laeger; 2006 Jun; 168(25):2457-62. PubMed ID: 16824370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma.
    Poo-Hwu WJ; Ariyan S; Lamb L; Papac R; Zelterman D; Hu GL; Brown J; Fischer D; Bolognia J; Buzaid AC
    Cancer; 1999 Dec; 86(11):2252-8. PubMed ID: 10590365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanoma of the ear: prognostic factors and surgical strategies.
    Jahn V; Breuninger H; Garbe C; Moehrle M
    Br J Dermatol; 2006 Feb; 154(2):310-8. PubMed ID: 16433802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elective, therapeutic, and delayed lymph node dissection for malignant melanoma of the head and neck: analysis of 1444 patients from 1970 to 1998.
    Fisher SR
    Laryngoscope; 2002 Jan; 112(1):99-110. PubMed ID: 11802046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of malignant melanoma.
    Kroon BB; Nieweg OE
    Ann Chir Gynaecol; 2000; 89(3):242-50. PubMed ID: 11079795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma.
    Turner RM; Bell KJ; Morton RL; Hayen A; Francken AB; Howard K; Armstrong B; Thompson JF; Irwig L
    J Clin Oncol; 2011 Dec; 29(35):4641-6. PubMed ID: 22067399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision.
    McKenna DB; Lee RJ; Prescott RJ; Doherty VR
    Br J Dermatol; 2004 Mar; 150(3):523-30. PubMed ID: 15030337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.
    Nowecki ZI; Rutkowski P; Nasierowska-Guttmejer A; Ruka W
    Ann Surg Oncol; 2006 Dec; 13(12):1655-63. PubMed ID: 17016755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognosis of malignant melanoma following dissection regional lymph node metastases].
    Sprakel B; Stenschke F; Unnewehr M; Ladas A; Senninger N
    Chirurg; 2003 Jan; 74(1):55-60. PubMed ID: 12552406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Results of elective lymph node excision in melanoma of the trunk].
    Zimmermann T; Buhr J; Kelm C; Padberg W
    Zentralbl Chir; 1996; 121(6):478-82. PubMed ID: 8767335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical management of patients with intermediate thickness melanoma: current role of elective lymph node dissection.
    Cole DJ; Baron PL
    Semin Oncol; 1996 Dec; 23(6):719-24. PubMed ID: 8970593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elective lymph node dissection in patients with primary melanoma of the trunk and limbs treated at the Sydney Melanoma unit from 1960 to 1991.
    Coates AS; Ingvar CI; Petersen-Schaefer K; Shaw HM; Milton GW; O'Brien CJ; Thompson JF; McCarthy WH
    J Am Coll Surg; 1995 Apr; 180(4):402-9. PubMed ID: 7719543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The case for minimal margins and delayed regional node dissection for high-risk cutaneous melanoma.
    Cascinelli N; Belli F
    Curr Opin Gen Surg; 1993; ():310-5. PubMed ID: 7584000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sentinel lymph node biopsy for melanoma: prognostic value and disadvantages in 300 patients].
    de Vries M; Jager PL; Suurmeijer AJ; Plukker JT; van Ginkel RJ; Hoekstra HJ
    Ned Tijdschr Geneeskd; 2005 Aug; 149(33):1845-51. PubMed ID: 16128183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis of patients with pathologic stage II cutaneous malignant melanoma.
    Roses DF; Provet JA; Harris MN; Gumport SL; Dubin N
    Ann Surg; 1985 Jan; 201(1):103-7. PubMed ID: 3966826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Preventive lymph node excision in the treatment concept of melanoma of the extremities].
    Binder J; Henneking K
    Zentralbl Chir; 1996; 121(6):474-7. PubMed ID: 8767334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma.
    Badgwell B; Xing Y; Gershenwald JE; Lee JE; Mansfield PF; Ross MI; Cormier JN
    Ann Surg Oncol; 2007 Oct; 14(10):2867-75. PubMed ID: 17671814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Sentinel lymph node dissection in patients with malignant melanoma. Diagnostic and therapeutic standards].
    Arens A; Osinga J; Schwipper V; Schober O; Tilkorn H; Liebau J
    Chirurg; 2003 Jul; 74(7):665-70. PubMed ID: 12883795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sentinel lymph node biopsy for the T1 (thin) melanoma: is it necessary?
    Nahabedian MY; Tufaro AP; Manson PN
    Ann Plast Surg; 2003 Jun; 50(6):601-6. PubMed ID: 12783009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.